Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Carcinoma, Non-Small-Cell Lung 244Melanoma 140Squamous Cell Carcinoma of Head and Neck 139Parkinson Disease 4, Autosomal Dominant Lewy Body 119Neoplasm Metastasis 105Triple Negative Breast Neoplasms 96Neoplasms 91Lung Neoplasms 90Breast Neoplasms 80Colorectal Neoplasms 70Carcinoma, Renal Cell 69Head and Neck Neoplasms 59Urinary Bladder Neoplasms 50Stomach Neoplasms 48Ovarian Neoplasms 46Endometrial Neoplasms 46Carcinoma, Transitional Cell 44Carcinoma, Hepatocellular 35Uterine Cervical Neoplasms 34Pancreatic Neoplasms 34Esophageal Neoplasms 27Recurrence 25Prostatic Neoplasms 25Carcinoma, Squamous Cell 25Carcinoma 25Sarcoma 24Brain Neoplasms 23Glioblastoma 22Hodgkin Disease 19Cholangiocarcinoma 19

Interventions

pembrolizumab 2Carboplatin 2tislelizumab 1cemiplimab 1aflutinib 1Pemetrexed 1Docetaxel 1Cisplatin 1Axitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Advanced Non-small Cell Lung Cancer × pembrolizumab × 1 year × Clear all
NCT06452277 2026-05-18

SOHO-02

Bayer

Phase 3 Recruiting
444 enrolled
Thoracic

Advanced Non-small Cell Lung Cancer

NCT06868732 2026-03-30

Evaluation of JSKN016 Combination Therapy in Subjects With NSCLC

Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Phase 1 Recruiting
288 enrolled
Thoracic

Advanced Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡